
Ep. 93 From Neoadjuvant and Perioperative Therapy to Surgery: Multidisciplinary Decisions in Early Stage NSCLC with Dr. John Lazar
19.11.2026
0:00
36:16
“If I have a complete pathological response, why do I need to get surgery?” It is one of the hottest questions in early-stage non-small cell lung cancer (NSCLC), and Dr. John Lazar hears it from his patients after neoadjuvant therapy. On this episode of the BackTable Lung Cancer Creator Weekend™, medical oncologist Dr. Kate Baker talks with Dr. Lazar, thoracic surgeon at Ascension Saint Thomas, about who should get neoadjuvant or perioperative therapy and how tumor size, nodal disease, histology, and molecular profiling shape the plan. They also discuss what a complete pathologic response does and does not tell a patient, why waiting more than six weeks from diagnosis to treatment raises the risk of upstaging, and how surgery changes after treatment has distorted the anatomy.
---
Get the BackTable apphttps://www.backtable.com/app
---
This podcast is supported by
AstraZenecahttps://www.astrazeneca.com/
---
Timestamps
00:00 - Introduction01:11 - Is Neoadjuvant or Perioperative Therapy the Standard?02:32 - Tumor Features, Molecular Profiling, and Why Treat First05:54 - Counseling on Pathologic Response08:26 - Surgery After Neoadjuvant Therapy09:42 - Getting Patients to Surgery: Toxicity and the Third Dose12:07 - Complete Response, Adjuvant Immunotherapy, and Whether Less Is More16:31 - Histology, Grade, and Biopsy Tissue21:42 - Complete Response, PD-L1, and EGFR and ALK Results24:36 - Counseling Patients and Smoking Cessation27:11 - Lobectomy, Segmentectomy, or Wedge Resection30:50 - Pitfalls: Communication and Time to Treatment34:22 - Closing Remarks
---
More about this episode
Dr. Kate Baker and Dr. John Lazar trade questions across the surgeon and medical oncologist divide on circulating tumor DNA, whether fewer neoadjuvant cycles could be enough, PD-L1 status, and the EGFR and ALK results that change neoadjuvant strategy. Dr. Lazar shares how he counsels patients before treatment, why none of his patients go to the operating room smoking, how he chooses between lobectomy, segmentectomy, and wedge resection, and why poor communication between teams is the most preventable pitfall on the way to a goal of 28 days from diagnosis to treatment.
---
Resources
He J, et al. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer (NeoADAURA). J Clin Oncol. 2025https://doi.org/10.1200/JCO-25-00883 Forde PM, et al. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer (CheckMate 816). N Engl J Med. 2025https://doi.org/10.1056/NEJMoa2502931
---
BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app
Weitere Episoden von „BackTable Tumor Board“



Verpasse keine Episode von “BackTable Tumor Board” und abonniere ihn in der kostenlosen GetPodcast App.








